Actinogen

Gain a direct line to Actinogen leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Webinars

General Meeting

Financial Calendar

Right to Receive Documents

Annual General Meeting

Investor Contacts

FAQs

Shareholders

Analyst Research

Announcements

Financial Results

Annual Reports

Corporate Presentations

Investors

Home

Invest

Share Price

US Newswires

Company Updates

Australian News

News

Inter

Investor Hub

Edison-First-Patient-Dosed-in-Phase-11b-XanaMIA-Study.pdf

This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way

 Edison Investment Research update Actinogen Medical – First patient dosed in Phase IIb XanaMIA study